CCL

Összesen 5 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM076939
035-os BibID:(WoS)000459818800010 (Scopus)85061921489 (PMID)30704923
Első szerző:Frey, Noelle
Cím:Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia : a randomised, double-blind, phase 2 study / Noelle Frey, Jun Ho Jang, Jeff Szer, Árpád Illés, Hee-Je Kim, Ron Ram, Beng H. Chong, Jacob M. Rowe, Elena Borisenkova, Jane Lisveld, Eric S. Winer, Azzeddine Cherfi, Vassilios Aslanis, Farhat Ghaznawi, Stephen Strickland
Dátum:2019
ISSN:2352-3026
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:The Lancet. Haematology. - 6 : 3 (2019), p. e122-e131. -
További szerzők:Jang, Jun Ho Szer, Jeff Illés Árpád (1959-) (belgyógyász, haematológus, onkológus) Kim, Hee-Je Ram, Ron Chong, Beng H. Rowe, Jacob M. Borisenkova, Elena Lisveld, Jane Winer, Eric S. Cherfi, Azzeddine Aslanis, Vassilios Ghaznawi, Farhat Strickland, Stephen
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

2.

001-es BibID:BIBFORM083564
035-os BibID:(WoS)000515522000013 (Scopus)85079841017
Első szerző:Gisslinger, Heinz
Cím:Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV) : a randomised, non-inferiority, phase 3 trial and its extension study / Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Viktor Rossiev, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiri Mayer, Vera Yablokova, Kurt Krejcy, Barbara Grohmann-Izay, Hans C. Hasselbalch, Robert Kralovics, Jean-Jacques Kiladjian, PROUD-PV Study Group
Dátum:2020
ISSN:2352-3026
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:The Lancet. Haematology. - 7 : 3 (2020), p. e196-e208. -
További szerzők:Klade, Christoph Georgiev, Pencho Krochmalczyk, Dorota Gercheva-Kyuchukova, Liana Egyed Miklós Rossiev, Viktor Dulicek, Petr Illés Árpád (1959-) (belgyógyász, haematológus, onkológus) Pylypenko, Halyna Sivcheva, Lylia Mayer, Jiri Yablokova, Vera Krejcy, Kurt Grohmann-Izay, Barbara Hasselbalch, Hans C. Kralovics, Robert Kiladjian, Jean-Jacques PROUD-PV Study Group
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM077363
035-os BibID:(WoS)000456000000026 (Scopus)85059506213
Első szerző:Horwitz, Steven
Cím:Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2) : a global, double-blind, randomised, phase 3 trial / Steven Horwitz, Owen A. O'Connor, Tim Illidge, Michelle Fanale, Ranjana Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Franck Morschhauser, Eva Domingo-Domenech, Giuseppe Rossi, Won Seog Kim, Tatyana Feldman, Anne Lennard, David Belada, Árpád Illés, Kensei Tobinai, Kunihiro Tsukasaki, Su-Peng Yeh, Andrei Shustov, Andreas Hüttmann, Kerry J. Savage, Sam Yuen, Swaminathan Iyer, Pier Luigi Zinzani, Zhaowei Hua, Meredith Little, Shangbang Rao, Joseph Woolery, Thomas Manley, Lorenz Trümper, ECHELON-2 Study Group
Dátum:2019
ISSN:2352-3026
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:The Lancet Haematology. - 393 : 10168 (2019), p. 229-240. -
További szerzők:O'Connor, Owen A. Illidge, Tim Fanale, Michelle Advani, Ranjana Bartlett, Nancy L. Christensen, Jacob Haaber Morschhauser, Franck Domingo-Domenech, Eva Rossi, Giuseppe Kim, Won Seog Feldman, Tatyana Lennard, Anne Belada, David Illés Árpád (1959-) (belgyógyász, haematológus, onkológus) Tobinai, Kensei Tsukasaki, Kunihiro Yeh, Su-Peng Shustov, Andrei Hüttmann, Andreas Savage, Kerry J. Yuen, Sam Iyer, Swaminathan Zinzani, Pier Luigi Hua, Zhaowei Little, Meredith Rao, Shangbang Woolery, Joseph Manley, Thomas Trümper, Lorenz ECHELON-2 Study Group
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

4.

001-es BibID:BIBFORM101133
035-os BibID:(WoS)000753947800012 (Scopus)85123802052
Első szerző:Schjesvold, Fredrik
Cím:Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN) : a randomised, head-to-head, open-label, phase 3 study / Schjesvold Fredrik H., Dimopoulos Meletios-Athanasios, Delimpasi Sosana, Robak Pawel, Coriu Daniel, Legiec Wojciech, Pour Ludĕk, Špička Ivan, Masszi Tamas, Doronin Vadim, Minarik Jiri, Salogub Galina, Alekseeva Yulia, Lazzaro Antonio, Maisnar Vladimir, Mikala Gábor, Rosinol Laura, Liberati Anna Marina, Symeonidis Argiris, Moody Victoria, Thuresson Marcus, Byrne Catriona, Harmenberg Johan, Bakker Nicolaas A., Hájek Roman, Mateos Maria-Victoria, Richardson Paul G., Sonneveld Pieter, OCEAN (OP-103) Investigators
Dátum:2022
ISSN:2352-3026
Megjegyzések:Background Melphalan flufenamide (melflufen), an alkylating peptide-drug conjugate, plus dexamethasone showed clinical activity and manageable safety in the phase 2 HORIZON study. We aimed to determine whether melflufen plus dexamethasone would provide a progression-free survival benefit compared with pomalidomide plus dexamethasone in patients with previously treated multiple myeloma. Methods In this randomised, open-label, head-to-head, phase 3 study (OCEAN), adult patients (aged >= 18 years) were recruited from 108 university hospitals, specialist hospitals, and community-based centres in 21 countries across Europe, North America, and Asia. Eligible patients had an ECOG performance status of 0-2; must have had relapsed or refractory multiple myeloma, refractory to lenalidomide (within 18 months of randomisation) and to the last line of therapy; and have received two to four previous lines of therapy (including lenalidomide and a proteasome inhibitor). Patients were randomly assigned (1:1), stratified by age, number of previous lines of therapy, and International Staging System score, to either 28-day cycles of melflufen and dexamethasone (melflufen group) or pomalidomide and dexamethasone (pomalidomide group). All patients received dexamethasone 40 mg orally on days 1, 8, 15, and 22 of each cycle. In the melflufen group, patients received melflufen 40 mg intravenously over 30 min on day 1 of each cycle and in the pomalidomide group, patients received pomalidomide 4 mg orally daily on days 1 to 21 of each cycle. The primary endpoint was progression-free survival assessed by an independent review committee in the intention-to-treat (ITT) population. Safety was assessed in patients who received at least one dose of study medication. This study is registered with ClinicalTrials.gov, NCT03151811, and is ongoing. Findings Between June 12, 2017, and Sept 3, 2020, 246 patients were randomly assigned to the melflufen group (median age 68 years [IQR 60-72]; 107 [43%] were female) and 249 to the pomalidomide group (median age 68 years [IQR 61-72]; 109 [44%] were female). 474 patients received at least one dose of study drug (melflufen group n=228; pomalidomide group n=246; safety population). Data cutoff was Feb 3, 2021. Median progression-free survival was 6middot8 months (95% CI 5middot0-8middot5; 165 [67%] of 246 patients had an event) in the melflufen group and 4middot9 months (4middot2-5middot7; 190 [76%] of 249 patients had an event) in the pomalidomide group (hazard ratio [HR] 0middot79, [95% CI 0middot64-0middot98]; p=0middot032), at a median follow-up of 15middot5 months (IQR 9middot4-22middot8) in the melflufen group and 16middot3 months (10middot1-23middot2) in the pomalidomide group. Median overall survival was 19middot8 months (95% CI 15middot1-25middot6) at a median follow-up of 19middot8 months (IQR 12middot0-25middot0) in the melflufen group and 25middot0 months (95% CI 18middot1-31middot9) in the pomalidomide group at a median follow-up of 18middot6 months (IQR 11middot8-23middot7; HR 1middot10 [95% CI 0middot85-1middot44]; p=0middot47). The most common grade 3 or 4 treatment-emergent adverse events were thrombocytopenia (143 [63%] of 228 in the melflufen group vs 26 [11%] of 246 in the pomalidomide group), neutropenia (123 [54%] vs 102 [41%]), and anaemia (97 [43%] vs 44 [18%]). Serious treatment-emergent adverse events occurred in 95 (42%) patients in the melflufen group and 113 (46%) in the pomalidomide group, the most common of which were pneumonia (13 [6%] vs 21 [9%]), COVID-19 pneumonia (11 [5%] vs nine [4%]), and thrombocytopenia (nine [4%] vs three [1%]). 27 [12%] patients in the melflufen group and 32 [13%] in the pomalidomide group had fatal treatment-emergent adverse events. Fatal treatment-emergent adverse events were considered possibly treatment related in two patients in the melflufen group (one with acute myeloid leukaemia, one with pancytopenia and acute cardiac failure) and four patients in the pomalidomide group (two patients with pneumonia, one with myelodysplastic syndromes, one with COVID-19 pneumonia). Interpretation Melflufen plus dexamethasone showed superior progression-free survival than pomalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:The Lancet Haematology. - 9 : 2 (2022), p. e98-e110. -
További szerzők:Dimopoulos, Meletios A. Delimpasi, Sosana Robak, Pawel Coriu, Daniel Legiec, Wojciech Pour, Ludĕk Špička, Ivan Masszi Tamás Doronin, Vadim Minarik, Jiri Salogub, Galina Alekseeva, Yulia Lazzaro, Antonio Maisnar, Vladimir Mikala Gábor Rosinol, Laura Liberati, Anna Marina Symeonidis, Argiris Moody, Victoria Thuresson, Marcus Byrne, Catriona Harmenberg, Johan Bakker, Nicolaas A. Hájek, Roman Mateos, Maria-Victoria Richardson, Paul G. Sonneveld, Pieter Illés Árpád (1959-) (belgyógyász, haematológus, onkológus) OCEAN (OP-103) Investigators
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM100470
Első szerző:Straus, David J.
Cím:Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1) : 5-year update of an international, open-label, randomised, phase 3 trial / Straus David J., Dugosz-Danecka Monika, Connors Joseph M., Alekseev Sergey, Illés Árpád, Picardi Marco, Lech-Maranda Ewa, Feldman Tatyana, Smolewski Piotr, Savage Kerry J., Bartlett Nancy L., Walewski Jan, Ramchandren Radhakrishnan, Zinzani Pier Luigi, Hutchings Martin, Munoz Javier, Lee Hun Ju, Kim Won Seog, Advani Ranjana, Ansell Stephen M., Younes Anas, Gallamini Andrea, Liu Rachael, Little Meredith, Fenton Keenan, Fanale Michelle, Radford John
Dátum:2021
ISSN:2352-3026
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:The Lancet Haematology. - 8 : 6 (2021), p. e410-e421. -
További szerzők:Dugosz-Danecka, Monika Connors, Joseph M. Alekseev, Sergey Illés Árpád (1959-) (belgyógyász, haematológus, onkológus) Picardi, Marco Lech-Maranda, Ewa Feldman, Tatyana Smolewski, Piotr Savage, Kerry J. Bartlett, Nancy L. Walewski, Jan Ramchandren, Radhakrishnan Zinzani, Pier Luigi Hutchings, Martin Munoz, Javier Lee, Hun Ju Kim, Won Seog Advani, Ranjana Ansell, Stephen M. Younes, Anas Gallamini, Andrea Liu, Rachael Little, Meredith Fenton, Keenan Fanale, Michelle Radford, John
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.